title: Dabigatran: how the drug company withheld important analyses.
authors: Deborah
authors: D
authors: Cohen
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004345:Drug Industry / Q000331:legislation & jurisprudence; D016903:Drug Monitoring; D005060:Europe; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran